Psychedelic drug approval race tightens; Compass Pathways faces nonprofit challenger

Compass Pathways, a leading biotech in psychedelic drug development, faces a tight race for first FDA approval as a nonprofit competitor advances. The outcome will shape regulatory precedent and market access for psychedelic therapies. Uncertainty remains over trial results and FDA stance.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works